Latest Shareholder Approvals News

DroneShield Limited has triggered the vesting of over 9 million performance options following a significant $200 million cash receipts milestone, reflecting rapid growth and a new incentive framework.

Insignia Financial has responded to ASX concerns over past disclosures of performance rights, affirming shareholder approvals and outlining improved compliance measures.

Multistack International Limited reported a net operating cash outflow of A$196,577 for the December quarter but maintains a solid cash buffer as it pursues the sale of its Australian subsidiary.

Multistack International Limited has announced plans to discontinue its current business operations and is working towards disposing of its Australian subsidiary after continued losses and cash burn.

Pilot Energy is seeking shareholder approval for a 1-for-25 consolidation of its securities to streamline its capital structure and boost investor appeal as it advances into carbon storage and clean energy projects.

Cyprium Metals has raised A$41 million through an oversubscribed equity placement and entitlement offer to accelerate exploration and production growth at its flagship Nifty Copper Complex and regional projects.

Codeifai Limited has raised $1.1 million through a share placement to fund the commercialisation of a quantum-secured platform and broaden its AI capabilities into new industrial sectors.

Global Uranium and Enrichment Limited has finalised the share and option scheme considerations for its acquisition by Snow Lake Resources, with directors backing the deal ahead of the upcoming shareholder vote.

Visionflex Group Limited reported a mixed quarter with a modest cash burn but strengthened its balance sheet through a significant debt-to-equity conversion and maintained solid funding capacity.

Falcon Metals has reported compelling high-grade gold results from its Blue Moon project in Victoria, extending mineralisation along strike and confirming the potential for a significant new gold reef. The company also advances exploration at Pyramid Hill and Errabiddy while maintaining a strong cash position.

Objective Corporation Limited has announced an on-market buy-back of up to 9.6 million ordinary shares, representing roughly 10% of its issued capital, set to run from February 2026 to February 2027.

Cambium Bio has strengthened its financial footing with a $0.6 million R&D tax refund and a $2.4 million strategic placement, setting the stage for pivotal Phase 3 clinical trials of its lead ophthalmology candidate.